In-licensing of BGB324 from Rigel
PharmaVenture Client Bergen Bio Licenses R428.
PharmaVentures Client BergenBio entered into an agreement for Rigel’s preclinical candidate, R428 (now referred to as BGB324), an Axl kinase inhibitor for oncology.
For press enquiries, please contact:
Senior Marketing Manager
+44 (0) 1865 332700